Innovative Blood Test Using SWIFT-seq Offers Less Invasive Diagnosis for Multiple Myeloma
A new blood test called SWIFT-seq offers a less invasive and highly detailed method for diagnosing and monitoring multiple myeloma, potentially replacing painful bone marrow biopsies with comprehensive genetic analysis from a blood sample.
Researchers at Dana-Farber Cancer Institute have introduced a groundbreaking blood test named SWIFT-seq that promises to revolutionize the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions such as Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM). Unlike traditional methods that rely on painful and invasive bone marrow biopsies, SWIFT-seq uses advanced single-cell sequencing technology to analyze circulating tumor cells (CTCs) directly from blood samples, providing a comprehensive genetic profile of the disease.
The study, published in Nature Cancer, demonstrates that SWIFT-seq can accurately detect CTCs in about 90% of patients with MGUS, SMM, or MM, including 95% of those with SMM and 94% of newly diagnosed MM patients. The ability to enumerate and characterize these cells based on their molecular barcode distinguishes this test from existing techniques like flow cytometry, which depend on cell surface markers.
This innovative approach not only counts circulating tumor cells but also assesses their genetic alterations, proliferation capacity, and gene expression signatures—all from a single blood draw. Such detailed insights enable improved risk stratification, disease monitoring, and potentially guide personalized treatment strategies.
Senior author Dr. Irene M. Ghobrial highlighted the significance of this development, stating that SWIFT-seq could outperform traditional FISH tests by providing a more accurate, less invasive method for genetic surveillance. Co-first author Dr. Romanos Sklavenitis-Pistofidis emphasized its potential to be a major advancement in myeloma diagnostics and patient care.
By capturing tumor biology and progression markers through a simple blood test, SWIFT-seq offers a promising alternative to standard biopsies, facilitating earlier detection, better risk assessment, and more tailored treatment plans, ultimately aiming to improve patient outcomes and deepen understanding of myeloma biology.
Source: https://medicalxpress.com/news/2025-08-blood-multiple-myeloma-alternative-bone.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Early Immune Challenges and Their Impact on Oral and Systemic Health
Early immune challenges such as HIV exposure can disrupt the oral microbiome's stability, impacting both dental and systemic health in children. Discover key insights from recent research highlighting the importance of early immune system health.
Relationship Between Emotional Demands in Personal Interaction Jobs and Increased Risk of Type 2 Diabetes
A new study reveals that high emotional and confrontational demands in jobs involving direct contact with people may significantly increase the risk of developing type 2 diabetes, especially when social support at work is low.
Rural Residents Experience Higher Rates of Chronic Pain, Study Finds
A study reveals that rural residents are more likely to suffer from chronic pain and rely on opioids, emphasizing the need for targeted early intervention strategies.
Addressing Resident-to-Resident Aggression in Nursing Homes for Improved Safety
Resident-to-resident aggression in nursing homes is a serious issue affecting resident safety, often linked to dementia. Learn how systems, staff training, and advocacy can help reduce risks and improve outcomes.